Company news

Theravance Biopharma, Inc. news in 2024

Theravance Biopharma, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

December 16, 2024

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

November 11, 2024

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

October 23, 2024

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease

October 17, 2024

Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

August 4, 2024

Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024

July 21, 2024

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 12, 2024

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

April 28, 2024

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

April 9, 2024

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 25, 2024

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

February 13, 2024

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

January 4, 2024

Calls in 2024

Decks in 2024